

Accepted Manuscript

Title: Open innovation in early drug discovery: Roadmaps and roadblocks

Author: Melvin Reichman Peter B. Simpson

PII: S1359-6446(15)00460-2

DOI: <http://dx.doi.org/doi:10.1016/j.drudis.2015.12.008>

Reference: DRUDIS 1731

To appear in:

Received date: 13-10-2015

Revised date: 26-11-2015

Accepted date: 21-12-2015



Please cite this article as: Reichman, M., Simpson, P.B., Open innovation in early drug discovery: Roadmaps and roadblocks, *Drug Discovery Today* (2015), <http://dx.doi.org/10.1016/j.drudis.2015.12.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Open innovation was born from a triple helix of paradigm shifts
- The zeitgeist for open innovation is now at a crucial inflection point
- The sensitivity of proprietary structure activity data remains a roadblock
- General schemata are summarized for a protected open innovation (POI) model
- The POI model is consistent with the academic and industrial missions
- POI is a path to achieving the 'FIPNet' model for transforming pharmaceutical R&D

Download English Version:

<https://daneshyari.com/en/article/10885754>

Download Persian Version:

<https://daneshyari.com/article/10885754>

[Daneshyari.com](https://daneshyari.com)